65,437 trials
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Overall Survival — 25.1; 21.6 percentage of participants — p=0.46
Whole Blood Donation and Leukoreduction
Primary: % of Red Blood Cells With Hemolysis — 0.29; 0.29 % of Red Blood Cells with Hemolysis
Hepatitis C Virus (HCV)
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 98.0 percentage of participants
Cancer of Pancreas · Pancreatic Neoplasm
Primary: Median Number of Passes to Establish Diagnosis — 1; 1 No. of passes
Brain Cancer · Glioblastoma
Primary: Progression Free Survival (PFS) — 4.11; 4.34 months
Plaque Psoriasis
Primary: Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) (Placebo and Ixekizumab) — 25; 88.7 percentage of participants — p=<0.001
Otorhinolaryngologic Surgical Procedures · Laser Therapy
Primary: Lowest Intraoperative Peripheral Oxygen Saturation (SpO2) — 97; 97 percentage of oxygen — p=0.7934
Small Cell Lung Cancer
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) — 5.2; 0; 0 percentage of participants
Atopic Dermatitis
Primary: Proportion of Modified Intent to Treat Subjects With Success on Investigator's Global Assessment of Disease Severity (Success Being a Score of Clear [0] or Almost Clear…
Mixed Phenotype Acute Leukemia · Previously Treated Myelodysplastic Syndrome · Recurrent Adult Acute Myeloid Leukemia
Primary: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) at the Maximum Tolerated Dose (MTD) for Decitabine When Given Together With G-CLAM Toxicities (DLTs)…
Emergence Delirium
Primary: Pediatric Anesthesia Emergence Delirium Score — 18; 18 units on a scale
Arthropathy of Hip Joint · Osteoarthritis, Hip
Primary: Pre-operative Narcotic Use — 30 Participants
Obsessive-Compulsive Disorder · Children · Anxiety Disorder
Primary: Children's Yale-Brown Obsessive Compulsive Scale Total Score — 20.59; 25.67 units on a scale — p=0.44
Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 10; 5; 2 Participants
Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lymphoma, Large B-Cell, Diffuse
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) in First 2 Cycles of Portion A — 0; 0; 0; 0 Participants